Heart failure & cardiomyopathies
Effect of Correcting Iron Deficiency on the Risk of Serious Infection in Heart Failure: Insights from the IRONMAN Trial
Authors' conclusion
In patients with heart failure and a reduced LVEF, correction of iron deficiency is not associated with an increased risk of hospitalization or death from infection, and may reduce such events, especially when TSAT is <20%.
Study context
- Population
- Symptomatic HF, left ventricular ejection fraction (LVEF) ≤45%, and transferrin saturation (TSAT) <20% or ferritin <100 μg/L
- Comparison
- Intravenous (IV) ferric derisomaltose vs usual care
- Primary endpoint
- Infection as the main reason for hospitalization or death (first and recurrent events)
Methodological detailspre-specified, blindly-adjudicated safety endpoint
- Pre-specified, blindly-adjudicated safety endpoint
Primary result
As reported in the abstract
Hospitalization or death due to infection
FDI vs Usual careEstimate (95% CI)P value
First event
HR 0.79(0.62–1.01)
P = 0.055Recurrent events
rate ratio 0.85(0.64–1.13)
P = 0.089Further findings
| Outcome | HR (95% CI) | P value | |
|---|---|---|---|
| Hospitalisation for infection (first event)5% fewer patients (absolute reduction) with FDI | 0.76 (0.49–0.98) | P = 0.032 | |
| 0.512Hazard ratio (log scale) |
Hospitalisation for infection (recurrent events)
- Similar trends for recurrent events
- HR 0.82, 95% CI 0.62-1.10
Hospitalisation for infection, by TSAT (subgroup)
- Reduction with ferric derisomaltose (FDI) restricted to patients with TSAT <20%
Original publication
Effect of Correcting Iron Deficiency on the Risk of Serious Infection in Heart Failure: Insights from the IRONMAN Trial. Eur J Heart Fail. Published 25 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →